3
Announcements
Trials
Browse
Landscape
Phase
Phase 2/3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Breast Neoplasms
13
cyclopia sequence
7
Neoplasms
5
Polycystic Ovary Syndrome
4
Prostatic Neoplasms
3
Multiple Myeloma
3
Lung Neoplasms
3
Leiomyoma
3
Head and Neck Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Vomiting
2
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Pain
2
Obesity
2
Neoplasms, Plasma Cell
2
Nausea
2
Hematologic Diseases
2
Fatigue
2
Depression
2
Weight Loss
1
Warts
1
Urinary Bladder Neoplasms
1
Testicular Neoplasms
1
Sleepiness
1
Sezary Syndrome
1
Prostatic Intraepithelial Neoplasia
1
Primary Myelofibrosis
1
Peripheral Nervous System Diseases
1
Pediatric Crohn's disease
1
Pdgfra-Associated Chronic Eosinophilic Leukemia
1
Interventions
Doxorubicin
6
pazopanib
5
Trabectedin
4
Radiotherapy
3
temsirolimus
2
eribulin
2
Sunitinib
2
Radiotherapy, Conformal
2
Ifosfamide
2
Dexamethasone
2
sitravatinib
1
selinexor
1
saracatinib
1
romidepsin
1
regorafenib
1
plitidepsin
1
pembrolizumab
1
palbociclib
1
olaratumab
1
milademetan
1
liposomal doxorubicin
1
lenvatinib
1
indolepropanol phosphate
1
efatutazone
1
cixutumumab
1
brigimadlin
1
avelumab
1
atezolizumab
1
Watchful Waiting
1
Topotecan
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Liposarcoma
×
Sugars
×
Clear all
NCT02606461
2023-01-23
SEAL
Karyopharm Therapeutics Inc
Phase 2/3
Completed
342 enrolled
36 charts